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Background: The aim of the study was to explore rhinitis therapy purchases in different Aus-
tralian regions for patients with and without additional respiratory disease, using both doctor’s 
prescriptions and over-the-counter (OTC) medications.
Patients and methods: It was a historical cohort study of pharmacy-related claims that 
included prescription or OTC rhinitis therapy, with or without asthma/COPD therapy, from 
January 2013 to December 2014.
Results: Overall, 4,247,193 prescription and OTC rhinitis treatments were purchased from 
909 pharmacies over a calendar year; the majority were single-therapy purchases for rhinitis 
only patients. More multiple-therapy was purchased for rhinitis and asthma/COPD patients 
(4.4%) than for rhinitis only patients (4.0%), with a greater proportion purchased in VIC, SA 
and TAS (4.7% of rhinitis only patients and 4.5% of rhinitis and asthma/COPD patients) than 
in other areas. Dual therapy of oral antihistamine (OAH) and intranasal corticosteroid (INS) 
were the most frequently purchased multiple-therapy, with higher purchasing rates for rhinitis 
and asthma/COPD patients (2.6%) than for rhinitis only patients (1.6%). The most frequently 
purchased single therapy was OAH (70.1% of rhinitis only patients and 57.3% of rhinitis and 
asthma/COPD patients). First-line INS therapy was more likely to be purchased for rhinitis and 
asthma/COPD patients (15.3% by prescription and 11.7% OTC) than for rhinitis only patients 
(5.0% by prescription and 9.2% OTC); however, geographical differences in the proportion of 
therapies purchased OTC were noted, with a lower proportion of OTC OAH and INS purchases 
in Queensland and the Northern Territory for patients with and without comorbid respiratory 
disease.
Conclusion: Purchases of first-line INS therapy are more likely for patients with comorbid 
respiratory disease if they have received prescriptions and information/advice from their general 
practitioner. The study results indicate a need for patient information/education at the point-of-
sale of OTC OAHs to enable patients to assess their nasal symptoms and receive treatment support 
from pharmacists. Greater availability to INSs in pharmacies as well as guidance from current 
guidelines and instruction in correct intranasal technique may also lead to greater uptake of INSs.
Keywords: asthma, chronic obstructive airways disease, intranasal corticosteroids, medication, 
oral antihistamines, over-the-counter, pharmacy
Introduction
Rhinitis is a chronic respiratory condition defined by one or more of the following 
nasal symptoms: nasal congestion, rhinorrhea, sneezing and/or itching.1 Rhinitis is 
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often categorized into allergic rhinitis (AR) and non-allergic 
rhinitis (NAR), with recent data suggesting that as many 
as 50–70% of patients suffer from a mixed form known as 
mixed rhinitis.2 Both AR and NAR are independent risk 
factors for new-onset asthma.1,3–5 Symptoms of rhinitis can 
also present in COPD.6 Nasal symptoms can be triggered 
by exposure to aeroallergens in sensitized individuals with 
AR, while changes in temperature and humidity can induce 
symptoms in those with NAR.5 AR is the most common type 
of rhinitis,7 affecting 19% of the Australian population,8 with 
different prevalence rates across Australian regions due to 
significant geographical variability in climatic conditions 
and allergen exposure.8,9
AR is associated with a variety of comorbidities such 
as conjunctivitis, rhinosinusitis and otitis media as well as 
asthma, which is considered to be part of the unified air-
way.3,5,10 In Australia, at least 30% of patients with known AR 
also have asthma and as many as 80% of asthma patients have 
coexisting AR.11 Untreated or poorly managed AR can pose a 
significant health problem due to its prevalence and negative 
impact on patients’ quality of life, causing sleep, disturbances 
resulting in daytime fatigue and affecting work productivity 
and school performance.12–14 The repercussions of poorly 
managed AR can also extend into coexisting asthma, where it 
can worsen asthma control and increase the risk of exacerba-
tions.3,15 Thus, it is fundamental that in asthma patients, coex-
isting AR is detected and treated with first-line AR therapy, 
given that over 60% of Australian adults with uncontrolled 
asthma have moderate-severe AR that is underreported and 
undertreated.16 It is also important that AR patients allergic 
to rye grass pollens, with or without a history of asthma, are 
made aware of the increased risk in certain weather conditions 
during the pollen season of “thunderstorm asthma” which 
can trigger severe asthma exacerbations leading to death and 
the use of preventative measures.17
AR management strategies encompass patient education, 
allergen minimization, pharmacotherapy and the addition of 
allergen-specific immunotherapy in severe cases of AR.3–5,18 
Intranasal corticosteroids (INSs) are recommended as first-
line therapy for moderate-severe and/or persistent AR and 
NAR in patients with or without lower airways disease. They 
are considered the most effective monotherapy for AR in both 
adults and children.3–5,18 INSs are effective in improving all 
symptoms of AR including ocular symptoms19 and are more 
effective than oral antihistamines (OAHs) and oral leukot-
riene receptor antagonists (LTRAs).20,21 Second-generation 
OAHs are recommended for mild intermittent AR.22 Combi-
nation intranasal therapy containing a corticosteroid and an 
antihistamine in a single device has been shown to deliver 
added efficacy greater than that attained by INS monotherapy, 
and for some patients the clinical benefit is significant.23 
While there is insufficient clinical evidence available to sup-
port the combined use of OAH and INS therapy,3,4 with most 
published evidence confirming no benefits gained by adding 
other AR treatments to INS therapy,24 high failure rates of 
INS monotherapy have been reported, resulting in frequent 
co-prescription of multiple treatments.25
AR is one of the most underestimated respiratory con-
ditions reported by physicians and patients.26 Its manage-
ment is often suboptimal and frequently complicated by 
delayed diagnosis and appropriate treatment because of 
attempts by patients to self-medicate with a wide range of 
over-the-counter (OTC) medication available from phar-
macies and patients do not consult a general practitioner 
(GP).26–29 Often the OTC treatments have been self-selected 
without seeking pharmacist advice.26 In most regions of 
Australia, many of the treatments for rhinitis are “pharmacy 
medicines” (Schedule 2), which are stored on open shelves 
and available OTC, without prescription and without the 
requirement of pharmacist intervention. Other treatments 
available without prescription are “pharmacist only medi-
cines” (Schedule 3), which are stored in a secure area away 
from the public and with the requirement of pharmacist 
intervention.30 However, in Queensland and the Northern 
Territory (QLD and NT), both Schedules 2 and 3 medicines 
are stored in a secure area away from the public and require 
pharmacist intervention.31
In Australia, apart from reported patterns and costs of 
single and multiple-therapy purchases from pharmacies 
for rhinitis,32 little is known about the nature and extent 
of rhinitis treatments purchases in different regions of 
Australia for patients with and without additional respi-
ratory disease. Moreover, examining medication use for 
patients with and without additional respiratory disease 
may provide evidence for intervention regarding screening 
and OTC medication counseling protocols for pharmacists, 
scheduling of medicines and prescribing policies. The study 
aimed to explore rhinitis therapy purchases in different 
Australian regions for patients with and without additional 
respiratory disease using both doctor’s prescriptions and 
OTC medications.
Patients and methods
This was a historical cohort study of pharmacy-related claims 
that included both prescription and OTC rhinitis therapy, 
with or without asthma/COPD therapy, from January 2013 to 
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December 2014. The study was registered with the European 
Network of Centers for Pharmacoepidemiology and Phar-
macovigilance (registration number ENCEPP/SDPP/8507) 
and approved by the Anonymised Data Ethics Protocols 
and Transparency (ADEPT) committee (approval reference 
number ADEPT0215).
Data source
A demographically representative dataset of pharmacy-
related claims was provided by NostraData (https://www.
nostradata.com.au/Public/Home/About), which included 
information from both doctor’s prescriptions and OTC sup-
ply. Of the estimated 5,240 pharmacies across Australia in 
2013, 77% were in QLD, New South Wales and Victoria.33 
The NostraData dataset contained data from 909 randomly 
selected pharmacies across Australia and provided repre-
sentative geographic coverage of all states/territories and 
the population as a whole, as shown in Table 1. Informa-
tion in this dataset describe the details of valid pharmacy 
transactions, including name(s) of product(s) purchased, 
prescription or OTC status, postcode of purchase and 
price paid.
Pharmacy purchases of at least one prescription or 
OTC rhinitis treatment with or without additional asthma/
COPD therapy during 2013 and 2014 were assessed from 
the pharmacy claims dataset. Prescription or OTC rhinitis 
treatments were used as a proxy for rhinitis, and asthma/
COPD treatments were used as a proxy for comorbid 
respiratory disease. Therapeutic classes of rhinitis treat-
ments included OAH; INS; intranasal antihistamine and 
corticosteroid combination; nonsteroidal nasal spray 
(NNS); LTRA; eye drop (ED) for allergic conjunctivitis; 
oral corticosteroid and injectable corticosteroid. Table 2 
shows a list of drugs included in each therapeutic class, 
the most representative in terms of prescription and OTC 
purchases and that are OTC (Schedule 2) and “pharmacist 
only medicines” (Schedule 3), and that require prescrip-
tion by a doctor (Schedule 4). LTRAs, oral and injectable 
corticosteroids were included as rhinitis therapy only if 
they were purchased without additional asthma/COPD 
treatment. Therapeutic classes of asthma/COPD treatments 
included short-acting β
2
 agonists, inhaled corticosteroids, 
long-acting β
2
 agonists, combination inhaled corticoste-
roids and long-acting β
2
 agonists therapy, short-acting 
muscarinic antagonists, long-acting muscarinic antago-
nists, cromones and theophyllins.
study outcomes
The following medication-related datasets were analyzed for 
patients with and without additional asthma/COPD therapy 
in each geographic region of Australia:
1. Count of therapies (ie, frequency of single and multiple 
rhinitis therapies of distinct drug class purchased in the 
same transaction).
2. Drug class of rhinitis therapy purchased as single therapy 
in the same transaction.
3. Drug class of rhinitis therapy purchased as multiple-
therapy in the same transaction.
4. Prescription and OTC “classes of therapies” purchased 
as single therapy in the same transaction.
Data analysis
Data were analyzed using MySQL and Microsoft Excel 
2011 software (Microsoft Corporation, Redmond, WA, 
USA). The sample characteristics of pharmacy transactions 
Table 1 sample characteristics of pharmacy transactions in different geographic regions of australia over 24 months
State/
territory
Pharmacies, 
n
All transactions, 
na
All transactions 
including rhinitis 
therapy, na
All transactions including 
rhinitis therapy without 
asthma/COPD therapy, n (%)a
All transactions including 
rhinitis therapy with asthma/
COPD therapy, n (%)a
acT 30 379,839 215,527 207,282 (96.2) 8,245 (3.8)
nsW 235 2,405,577 1,243,143 1,186,927 (95.5) 56,216 (4.5)
nT 3 43,472 21,328 20,416 (95.7) 912 (4.3)
QlD 210 1,738,886 870,898 836,007 (96.0) 34,891 (4.0)
sa 40 382,983 184,013 175,734 (95.5) 8,279 (4.5)
Tas 25 168,083 74,339 71,507 (96.2) 2,832 (3.8)
Vic 203 1,895,063 907,978 873,903 (96.2) 34,075 (3.8)
Wa 119 1,320,569 729,967 702,720 (96.3) 27,247 (3.7)
Total 909 8,334,472 4,247,193 4,074,495 (95.9) 172,697 (4.1)
Notes: aindividual patients cannot be tracked in this dataset. The data shown are the number of pharmacy transactions.
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in Australia were summarized using descriptive statistics. 
Pharmacy transactions during the study period were analyzed 
together and reported as average numbers and percentages 
per calendar year. To account for differences in climate and 
drug provision policies across Australia, data were ana-
lyzed separately for the following geographic areas: New 
South Wales and Australian Capital Territory; QLD and 
NT; Victoria, South Australia and Tasmania (VIC, SA and 
TAS); Western Australia. Count of therapies are shown as 
single, multiple and total number of therapies and recorded 
as absolute numbers and percentages. Combinations of dif-
ferent classes of therapies are recorded as absolute numbers 
and percentages. Numbers of OTC therapies were tallied for 
each combination of therapies.
Results
Table 1 shows the sample characteristics of pharmacy trans-
actions across different Australian regions over 12 months. 
Of the 8,334,472 pharmacy transactions assessed, 4,247,193 
(51%) included rhinitis therapy, of which 4,074,496 (96%) 
were without asthma/COPD therapy and 172,697 (4%) were 
with additional asthma/COPD therapy.
count of rhinitis therapies of distinct 
drug class in the same transaction with 
and without additional asthma/cOPD 
therapy
Of the 4,074,496 transactions for which rhinitis only therapy 
was purchased, 3,909,923 (96.0%) were transactions that 
included a single drug class and 164,573 (4.0%) included 
multiple drug classes in the same transaction from pharma-
cies across all Australian regions.
Of the 172,697 transactions for which rhinitis and asthma/
COPD therapy was purchased, 165,064 (95.6%) were trans-
actions that included a single drug class and 7,633 (4.4%) 
included multiple drug classes in the same transaction from 
pharmacies across all Australian regions.
Differences between australian regions
Figure 1 shows the proportion of transactions where multiple 
“classes” of rhinitis therapy were purchased for rhinitis only 
patients and those with asthma/COPD from pharmacies 
in each Australian region. More multiple-therapy (4.7% 
of rhinitis only patients and 4.5% of rhinitis and asthma/
Table 2 list of drugs included in each therapeutic class
Oral antihistamine Intranasal 
corticosteroid 
Nonsteroidal 
nasal spray, ie, 
other nasal topical 
treatment
Intranasal 
combination 
antihistamine/
corticosteroid
Leukotriene 
receptor 
antagonist 
Eye drop for allergic 
conjunctivitis
acrivastinea Beclomethasone 
dipropionatea
azelastine 
hydrochloridea
Azelastine/fluticasone 
propionatec
Montelukastc Ketotifena
alimemazine tartrateb Budesonidea ipratropium bromidea Zafirlukastc lodoxamidea
alimemazine tartrate fortec Fluticasone 
propionatea
Oxymetazoline 
hydrochloridea
Olopatadinec
cetirizinea Fluticasone furoatec cromolyna sodium cromoglycatea
chlorphenaminea Mometasone furoatea ephedrine 
hydrochloridec
cyproheptadine hydrochlorideb Triamcinolone 
acetonidea
Xylometazoline 
hydrochloridea
Desloratadinea sodium 
cromoglycatea
 
Diphenhydramineb  Oxymetazoline 
hydrochloridea
Doxylamineb levocabastinea
Fexofenadinea Tramazolinea  
loratadinea
Pheniraminea
Promethazine hydrochlorideb
Notes: aschedule 2, available over-the-counter in all australian regions except Queensland and the northern Territory where they are stored in a secure area with 
the requirement of pharmacist intervention. bschedule 3, “pharmacist only medicines” that are stored in a secure area with the requirement of pharmacist intervention. 
cschedule 4, prescription medicines. 
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COPD patients) was purchased in VIC, SA and TAS than 
in other areas.
Drug class of rhinitis therapy purchased 
as single therapy with and without 
additional asthma/cOPD therapy in the 
same transaction
Of the 4,074,496 transactions for which rhinitis only therapy 
was purchased, 2,856,342 (70.1%) were single-therapy pur-
chases of OAH, 555,672 (13.6%) were INS purchases and 
415,670 (10.2%) were NNS purchases from pharmacies 
across all Australian regions. LTRA, intranasal combination 
antihistamine/corticosteroid and ED drug classes accounted 
for the remaining 2.1% transactions for rhinitis only single-
therapy purchases.
Of the 172,697 transactions for which rhinitis and 
asthma/COPD therapy was purchased, 99,027 (57.3%) were 
single-therapy purchases of OAH, 44,501 (25.8%) were INS 
purchases and 12,913 (7.5%) were NNS purchases from phar-
macies across all Australian regions. ED drug classes and an 
intranasal combination of antihistamine with corticosteroid 
accounted for the remaining 5.4% transactions for rhinitis 
and asthma/COPD therapy single-therapy purchases.
Differences between australian regions
Figure 2 shows the proportion of transactions where OAH, 
INS and NNS were purchased as single therapy for rhinitis 
only patients and those with asthma/COPD from pharmacies 
in each Australian region. More OAHs (73.5% of rhinitis only 
patients and 60.1% of rhinitis and asthma/COPD patients) 
and fewer INSs (11.0% of rhinitis only patients and 23.6% 
of rhinitis and asthma/COPD patients) were purchased in 
QLD and NT than in other areas.
Drug class of rhinitis therapy purchased 
as multiple-therapy with and without 
additional asthma/cOPD therapy in the 
same transaction
Of the 4,074,496 transactions for which rhinitis only therapy 
was purchased, 64,391 (1.6%) were multiple-therapy pur-
chases of both OAH and INS and 9,171 (0.2%) were multiple-
therapy purchases of both INS and NNS from pharmacies 
across all Australian regions. Other combinations accounted 
for the remaining 2.2% of multiple-therapy transactions.
Of the 172,697 transactions for which rhinitis and asthma/
COPD therapy was purchased, 4,449 (2.6%) were multiple-
therapy purchases of both OAH and INS and 560 (0.3%) 
were multiple-therapy purchases of both INS and NNS from 
pharmacies across all Australian regions. Other combina-
tions accounted for the remaining 1.1% of multiple-therapy 
transactions.
Differences between australian regions
Figure 3 shows the proportion of transactions where treat-
ment combinations of OAH and INS and INS and NNS were 
purchased for rhinitis only patients and those with asthma/
COPD from pharmacies in each Australian region. A lower 
proportion of dual OAH and INS treatment (1.0% of rhinitis 
5.0
4.0
3.0
2.0
%
 o
f t
ra
ns
ac
tio
ns
1.0
0
NSW and ACT QLD and NT
Australian geographic areas
VIC, SA
and TAS
WA
Rhinitis only patients
Rhinitis and asthma/COPD
patients
Figure 1 Proportion of transactions where multiple “classes” of rhinitis therapy purchased without asthma/cOPD therapy from pharmacies in nsW and acT (n=1,394,209); 
QlD and nT (n=856,423); Vic, sa and Tas (n=1,121,144); and Wa (n=702,720) and with asthma/cOPD therapy in nsW and acT (n=64,461); QlD and nT (n=35,803); 
Vic, sa and Tas (n=45,186); and Wa (n=27,247).
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only patients and 2.1% of rhinitis and asthma/COPD patients) 
was purchased in QLD and NT than in other areas.
Prescription and OTc “classes of 
therapies” purchased as single therapy 
without additional asthma/cOPD therapy 
in the same transaction
Of the 3,909,923 transactions for which rhinitis only therapy 
was purchased that included a single drug class, 2,626,934 
(67.2%) and 236,680 (6.0%) were OTC and prescription OAH 
purchases, respectively; 359,899 (9.2%) and 196,226 (5.0%) 
were OTC and prescription INS purchases, respectively; and 
412,788 (10.6%) and 2,898 (0.07%) were OTC and prescription 
NNS purchases, respectively. For rhinitis only patients, more 
single therapy was purchased OTC than by prescription, and the 
most frequently purchased single therapy was OAH (67.2%), 
followed by NNS (10.6%) and INS (9.2%), all OTC.
Differences between australian regions
Figure 4 shows the proportion of transactions for which both 
OTC and prescription OAH, INS and NNS were purchased 
as single therapy for rhinitis only patients from pharmacies 
in each Australian region. Fewer OTC OAHs (55.8%), more 
prescription OAHs (20.3%) and fewer OTC INSs (6.6%) 
were purchased for rhinitis only patients in QLD and NT 
than in other areas.
80
70
60
50
40
30
20
%
 o
f t
ra
ns
ac
tio
ns
10
0
INS
Classes of single therapy for rhinitis only patients and rhinitis and asthma/COPD patients
OAH NNS NNS and
asthma/COPD
NSW and ACT
QLD and NT
VIC, SA and TAS
WA
INS and
asthma/COPD
OAH and
asthma/COPD
Figure 2 Proportion of transactions where Oah, ins and OnT were purchased as single therapy without asthma/cOPD therapy from pharmacies in nsW and acT 
(n=1,394,209); QlD and nT (n=856,423); Vic, sa and Tas (n=1,121,144); and Wa (n=702,720) and with asthma/cOPD therapy in nsW and acT (n=64,461); QlD and 
nT (n=35,803); Vic, sa and Tas (n=45,186); and Wa (n=27,247).
Abbreviations: Oah, oral antihistamine; ins, intranasal corticosteroid; nns, non-steroidal nasal spray; OnT, other nasal topical treatment.
4
3.5
3
2.5
2
1.5
1
0.5
0
OAH + INS INS + NNS
NSW and ACT
QLD and NT
VIC, SA and TAS
WA
Dual therapy for rhinitis only patients and rhinitis and asthma/COPD patients
INS + NNS and
asthma/COPD
OAH + INS and
asthma/COPD
%
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Figure 3 Proportion of transactions where dual Oah and intranasal corticosteroid therapy and dual intranasal corticosteroid and nns were purchased without asthma/
cOPD therapy from pharmacies in nsW and acT (n=1,394,209); QlD and nT (n=856,423); Vic, sa and Tas (n=1,121,144); and Wa (n=702,720) and with asthma/cOPD 
therapy in nsW and acT (n=64,461); QlD and nT (n=35,803); Vic, sa and Tas (n=45,186); and Wa (n=27,247).
Abbreviations: Oah, oral antihistamine; ins, intranasal corticosteroid; nns, non-steroidal nasal spray.
 
Pr
ag
m
at
ic 
an
d 
O
bs
er
va
tio
na
l R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
30
-O
ct
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Pragmatic and Observational Research 2018:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
49
Real-life treatment of rhinitis in australia
Prescription and OTc “classes of 
therapies” purchased as single therapy 
with additional asthma/cOPD therapy in 
the same transaction
Of the 165,064 transactions for which rhinitis only therapy 
was purchased that included a single drug class, 85,420 
(51.7%) and 14,011 (8.5%) were OTC and prescription OAH 
purchases, respectively; 19,265 (11.7%) and 25,326 (15.3%) 
were OTC and prescription INS purchases, respectively; and 
12,538 (7.6%) and 376 (0.2%) were OTC and prescription 
NNS purchases, respectively. For rhinitis and asthma/COPD 
patients, the most frequently purchased single therapy was 
OTC OAH (51.7%), followed by prescription INS (15.3%) 
and OTC INS (11.7%).
Differences between australian regions
Figure 5 shows the proportion of transactions for which both 
OTC and prescription OAH, INS and NNS were purchased 
as single therapy for rhinitis and asthma/COPD patients from 
pharmacies in each Australian region. In QLD and NT, fewer 
OTC OAHs and INSs (39.8% and 8.5%, respectively) and 
more prescription OAHs (23.0%) were purchased for rhinitis 
and asthma/COPD patients than in other areas.
Discussion
This study provides valuable insight into the nature and extent 
of rhinitis therapy purchases in different Australian regions 
for patients with and without comorbid respiratory disease 
during a calendar year. It provides valid transaction data on 
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Figure 4 Proportion of transactions where both OTc and prescription Oahs, inss and nnss were purchased as single therapy without asthma/cOPD therapy from 
pharmacies in nsW and acT (n=1,337,146); QlD and nT (n=835,375); Vic, sa and Tas (n=1,068,786); and Wa (n=676,398).
Abbreviations: Oah, oral antihistamine; ins, intranasal corticosteroid; nns, non-steroidal nasal spray; OTc, over-the-counter.
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Figure 5 Proportion of transactions where both OTc and prescription Oahs, inss and nnss were purchased as single therapy with asthma/cOPD therapy from 
pharmacies in nsW and acT (n=61,428); QlD and nT (n=34,754); Vic, sa and Tas (n=43,219); and Wa (n=26,166).
Abbreviations: Oah, oral antihistamine; ins, intranasal corticosteroid; nns, non-steroidal nasal spray; OTc, over-the-counter.
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single- and multiple-therapy purchases in different Australian 
regions, the way in which rhinitis therapy is purchased, the 
prescribing behaviors of GPs and self-medication behaviors 
of patients in a real-life setting. Our study revealed that the 
majority of transactions were single-therapy purchases for 
rhinitis only patients. More multiple-therapy was purchased 
for rhinitis and asthma/COPD patients (4.4%) than for rhinitis 
only patients (4.0%), with a greater proportion purchased in 
VIC, SA and TAS (4.7% of rhinitis only patients and 4.5% 
of rhinitis and asthma/COPD patients) than in other areas. 
Dual therapies of OAH and INS were the most frequently 
purchased multiple-therapy, with higher purchasing rates for 
rhinitis and asthma/COPD patients (2.6%) than for rhinitis 
only patients (1.6%). OAHs were the most frequently pur-
chased single therapy (70.1% of rhinitis only patients and 
57.3% of rhinitis and asthma/COPD patients). INS therapy 
was more likely to be purchased for rhinitis and asthma/
COPD patients (15.3% by prescription and 11.7% OTC) 
than for rhinitis only patients (5.0% by prescription and 9.2% 
OTC); however, there were geographical differences in the 
proportion of therapies purchased OTC, with a lower propor-
tion of OTC OAH and INS purchases in QLD and NT for 
both patients with and without comorbid respiratory disease. 
Our study revealed that patients overall purchased OTC 
OAHs (70.1% of rhinitis only patients and 57.3% of rhinitis 
and asthma/COPD patients) and that first-line INS therapy 
was more likely to be purchased for rhinitis and asthma/
COPD patients (15.3% by prescription and 11.7% OTC) 
than for rhinitis only patients (5.0% by prescription and 9.2% 
OTC). Many studies have shown that most single therapy is 
purchased OTC than by prescription, and most often OAHs 
are purchased,14,25,28,34–37 which are not clinically effective 
or cost-effective.3,5,18 Our results are consistent with those 
from a recent community pharmacy-based study in Austra-
lia, where the majority of AR patients who had visited the 
pharmacy self-selected their medications, most of which 
were OTC OAHs, and 71% of OTC purchases of OAHs 
were self-selected by patients without seeking pharmacist 
advice.26 Therefore, we can hypothesize that if patients had 
interacted with the pharmacist, the proportion of patients 
with comorbid respiratory disease who select OTC first-line 
INS would increase. Our study showed that first-line INS 
therapy was more likely to be purchased for patients with 
comorbid respiratory disease, which could be due to that fact 
that these patients are more likely to visit their GP to receive 
prescriptions and information/education, are better informed 
and thus more likely to purchase appropriate OTC treatment 
and less likely to switch prescription medications.14,25,35 By 
contrast, rhinitis only patients are more likely to self-medicate 
with OTC medication, often self-selecting and switching 
medication, formulations and brands without being informed 
or seeking medical advice, in pursuit of finding a treatment 
that they perceive effectively controls their symptoms.14,26,36,38 
Given that INSs are first-line rhinitis therapy for patients with 
and without comorbid respiratory disease,3,5,18 INS therapy 
continues to be underused (and OAHs overused) by patients 
overall. Underuse of INSs has been previously reported in 
the Australian population, and major reasons identified for 
not using INSs included a dislike for nasal sprays, lack of 
knowledge about INS use, lack of perceived effectiveness 
and possible side effects.37 Discontinuation of INS therapy is 
also a common phenomenon among AR sufferers, with major 
reasons for stopping INS therapy being lack of acceptable 
efficacy, decline in effect over time, unpleasant side effects 
and concerns about dependence.37,39 As adequate adherence 
to continuous maintenance INS therapy and correct intranasal 
technique are factors that can contribute to rhinitis symptom 
control, appropriate patient information/education at the 
point-of-sale of OTC treatments and pharmacist support may 
lead to greater uptake of INSs, higher patient satisfaction 
rates with INS therapy and, by extension, improvements in 
the long-term management of rhinitis in primary care.
In this study, there were geographical differences in the 
proportion of therapies purchased OTC, with a lower pro-
portion of OTC OAH and INS purchases in QLD and NT 
for rhinitis patients with and without comorbid respiratory 
disease. In QLD and NT, OTC Schedule 2 medicines (which 
are accessible to the public in all other regions) must be stored 
in a secure area away from the public with the requirement 
of pharmacist intervention31 and may explain the lower pro-
portion of OTC OAH and OTC INS purchases (as single and 
dual therapy) in QLD and NT for patients with and without 
comorbid respiratory disease. Thus, information and advice 
on appropriate medication use for rhinitis is most likely to 
be provided by primary care providers in QLD and NT, as 
fewer OTC treatments are available on open shelves for self-
selection by patients, with most of the treatments available 
requiring pharmacist intervention or by prescription.
This large-scale study showed that more multiple-therapy 
was purchased for rhinitis and asthma/COPD patients (4.4%) 
than for rhinitis only patients (4.0%), with a greater propor-
tion purchased in VIC, SA and TAS (4.7% of rhinitis only 
patients and 4.5% of rhinitis and asthma/COPD patients) 
than in other areas. The use of multiple-therapy to manage 
AR symptoms has been well documented by a number of 
studies.14,25,40,41 Almost 15% of patients add OTC medications 
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to supplement prescribed or OTC medication for symptoms 
that are no longer managed with current treatment.14,25 Also, 
many patients receiving prescribed monotherapy at the start 
of the pollen season frequently return to their GP as the pol-
len season progresses, to co-prescribe multiple treatments or 
change treatment.25 Patient adherence to treatment appropri-
ately prescribed by their GP is also known to be poor.14,34,40 
Uncontrolled rhinitis symptoms can worsen asthma control as 
well as increasing the number of GP visits35,42 and may offer 
a possible explanation for higher rates of multiple-therapy 
purchases for rhinitis and asthma/COPD patients, as this 
patient cohort is more likely to have moderate-severe disease 
with persistent symptoms and be prescribed multiple-therapy 
by their GP.12,25,43 Compared to other Australian regions, VIC, 
SA and TAS had the highest multiple-therapy purchase rate, 
which is not surprising given that the prevalence rates of AR 
in VIC and SA are significantly higher than the rate for all 
of Australia,9 and possibly a reflection of high exposure to 
common clinically relevant seasonal allergens such as grass 
pollens including perennial ryegrass, timothy grass and small 
wind-distributed pollens from trees and weeds.44 Moreover, 
VIC has higher peak pollen counts than many other regions 
of Australia, due to the impact of springtime northerly winds 
that carry pollen from grasslands north of its border.44
Dual therapy of OAH and INS was the most common 
multiple-therapy purchased in this study, with higher pur-
chasing rates for rhinitis and asthma/COPD patients (2.6%) 
than for rhinitis only patients (1.6%), despite the lack of 
clinical evidence supporting this practice,3,4 which can incur 
additional costs (including costs associated with side effects 
from inappropriate medication use) to the patient.14,29,32,38 
This dual-therapy regimen frequently used by patients when 
monotherapy fails (whether OAH or INS) has been well 
documented by a number of studies.25,40,41 Failure of INS 
monotherapy in controlling rhinitis symptoms could be due 
to poor intranasal device technique,37 poor adherence to long-
term therapy, polysensitization,45 comorbidities,3–5,18 mixed 
rhinitis,1,2 misdiagnosis of rhinitis46 and severe chronic upper 
airways disease.12 Since dual-therapy purchase rates were 
the highest for patients with comorbid respiratory disease, 
health care provider (HCP) educational activities targeting 
appropriate investigation and management of rhinitis are 
required to ensure that patients use guideline-recommended 
medications appropriately.
Despite the fact that as many as 80% of patients with aller-
gic asthma have coexisting AR in Australia,11 our study found 
that the majority or rhinitis therapy transactions were without 
additional asthma/COPD therapy. A possible explanation 
for this finding could be that a proportion of rhinitis only 
transactions were for patients with undiagnosed respiratory 
conditions such as asthma and COPD. Given that asthma 
and rhinitis are considered as part of a unified airway,10 it 
is recommended that in patients with persistent AR, HCPs 
should screen for asthma, and in those with asthma, they 
should screen for rhinitis.3,5,18 Other possible explanations for 
this finding were that a proportion of rhinitis only transactions 
were destined to individuals with lower respiratory conditions 
or that most people with rhinitis and comorbid respiratory dis-
ease may not manage their symptoms with pharmacotherapy 
from pharmacies but rather immunotherapy.
Strengths and limitations of this 
study
The strength of this study lies in the fact that it is the first 
large-scale Australian study that used a demographically 
representative dataset of valid pharmacy-related claims, 
providing information on 4,247,193 rhinitis treatments for 
“real-life” patients over a calendar year. A major strength 
of this study was its observational nature, which enabled a 
depiction of real-life rhinitis treatment purchases via doctor’s 
prescriptions and OTC supply across Australia. This would 
have been difficult to capture through surveys that rely on 
prescriber and patient recall for reported outcomes, which 
can underestimate or overestimate patient and prescriber 
behavior. Moreover, the study captured valuable information 
regarding prescribing and self-medication trends, as well as 
the extent to which rhinitis management occurs within the 
Australian community pharmacy setting, as the majority 
of treatments options for rhinitis are available without a 
prescription.
There were several limitations of the study, which 
included the cross-sectional design, lack of demographic 
characteristics and lack of follow-up data, which may have 
resulted in multiple-therapy rates being underestimated, as 
individual patients may have purchased additional rhinitis 
treatments at different time points. This has been reported in 
a community-based longitudinal study in the UK, whereby 
16% of patients purchased additional therapies 5 days after 
the original purchase, with 16% and 18% purchasing addi-
tional therapies 4 and 8 weeks later, respectively.36 Another 
limitation of the study was the use of prescription and OTC 
rhinitis therapy purchases as a proxy for a diagnosis of rhi-
nitis as well as the use of asthma/COPD therapy purchases 
as a proxy for a diagnosis of asthma or COPD. However, it 
is plausible that treatments classified as rhinitis therapy may 
have been purchased OTC or by prescription for another 
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indication such as eczema or food allergy, even though a study 
based in the UK had found that over 60% of patients who 
were prescribed OAHs had a rhinitis diagnosis.47 Moreover, 
it may be plausible that EDs classified as rhinitis therapy may 
have been purchased for allergic conjunctivitis in the absence 
of rhinitis, even though a population-based study had found 
that up to 70% of patients with AR also had allergic con-
junctivitis.48 Finally, it was not possible to confirm whether 
multiple-therapy purchases in the same transaction were all 
intended for the same patient, or to record purchases of rhi-
nitis therapy from pharmacies outside NostraData coverage.
Conclusion
Patients overall are purchasing OTC OAHs, which are not 
clinically effective or cost-effective. Purchases of first-line 
INS therapy are more likely for patients with comorbid 
respiratory disease if they have received prescriptions and 
information/advice from their GP. The study results indicate 
a need for patient information/education at the point-of-
sale of OTC OAHs to enable patients to assess their nasal 
symptoms and receive treatment support from pharmacists. 
Greater availability to INSs in pharmacies as well as guidance 
from current guidelines and instruction in correct intranasal 
technique may also lead to greater uptake of INSs.
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